People · Operator
Named in public records as an officer, director or promoter · active 2019–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Variant Bio, Inc. | — | Biotechnology | Series D+ | $127.7M | $2.8B | 2019 |
Akhila Kosaraju at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Akhila Kosaraju on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Adam Goulburn | 1 | 10 |
| Stuart Nagae | 1 | 9 |
| Josh Wolfe | 1 | 8 |
| Bob More | 1 | 6 |
| Julie Sunderland | 1 | 5 |
| Elena Viboch | 1 | 4 |
| Andrew Farnum | 1 | 1 |
| Stephane Castel | 1 | 1 |
| Kaja Wasik | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.